Treatment of infantile haemangiomas: recommendations of a European expert group

Peter H. Hoeger, John I. Harper, Eulalia Baselga, Damien Bonnet, Laurence M. Boon, Marta Ciofi Degli Atti, Maya El Hachem, Arnold P. Oranje, Agneta Troilius Rubin, Lisa Weibel, Christine Léauté-Labrèze

Research output: Contribution to journalArticle


With a prevalence of 2.6–4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript. Conclusion: Oral propranolol is the first-line agent for the treatment of complicated IH.

Original languageEnglish
Pages (from-to)855-865
Number of pages11
JournalEuropean Journal of Pediatrics
Issue number7
Publication statusPublished - May 29 2015


  • Complications
  • Haemangioma
  • Infants
  • Therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Treatment of infantile haemangiomas: recommendations of a European expert group'. Together they form a unique fingerprint.

  • Cite this

    Hoeger, P. H., Harper, J. I., Baselga, E., Bonnet, D., Boon, L. M., Atti, M. C. D., El Hachem, M., Oranje, A. P., Rubin, A. T., Weibel, L., & Léauté-Labrèze, C. (2015). Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics, 174(7), 855-865.